Nitric oxide signaling in the ischemic postconditioning of human heart muscle (RCD code: III)
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2016, Vol 2, Issue 6
Abstract
Background: Ischemic heart conditioning is well documented to trigger the intrinsic protective mechanisms of resistance against ischemia/reperfusion (I/R) injury. Previous studies on animal model have suggested that the nitric oxide (NO) mediates the beneficial effect of ischemic postconditioning (POC). We tested the hypothesis that POC provide cardioprotection in the NO-dependent mechanism in the human myocardium. Methods: Human atrial trabeculae were subjected to simulated I/R injury. To achieve POC triple brief hypoxia periods were followed by the lethal hypoxia. Non-selective inhibitor of NO synthase: NG-monomethyl-L-arginine (L-NMMA) was used at the time of re-oxygenation in the POC protocol. Contractility of the myocardium was assessed as the maximal force of a contraction (Amax), the rate of rise of the force of a contraction (Slope L) and cardiac muscle relaxation – as the rate of decay of the force of a contraction (Slope T). Results: Co-application of L-NMMA with POC resulted in the decrease of Amax, Slope L and Slope T during re-oxygenation period as compared to POC only. Conclusions: At re-oxygenation period, the blockade of NO synthesis has deleterious effect on systolic and diastolic function of human myocardium, as well as attenuates the beneficial effect of ischemic.
Authors and Affiliations
Marcin Kunecki, Wojciech Płazak, Piotr Podolec, Tomasz Roleder, Jolanta Biernat, Marek Deja, Krzysztof Gołba
Keywords
Related Articles
- EP ID EP248094
- DOI 10.20418/jrcd.vol2no6.228
- Views 107
- Downloads 0
Transcatheter closure of perimembranous ventricular septal defect with muscular VSD occluder after infective endocarditis in a patient with previous primum atrial septal defect closure, prosthetic aortic and mitral valves replacement. (RCD code IV‑2B.3)
Ventricular septal defect (VSD) is the most common congenital heart defect at birth but is relatively rare in adult population. Apart from congenital, VSD may also be acquired. It can be caused by trauma, myocardial infa...
Ebstein Anomaly
Ebstein anomaly (EA) is a rare congenital malformation of the heart that is characterized by apical displacement of the septal and posterior tricuspid valve leaflets, with atrialization of the right ventricle and variabl...
The role of pharmacotherapy in the treatment of chronic thromboembolic pulmonary hypertension (RCD code: II-1A.5)
Chronic thromboembolic pulmonary hypertension (CTEPH) is a debilitating disease caused by chronic obstruction of major pulmonary arteries. The median age of patients at diagnosis of CTEPH is 63 years and both genders are...
Patient with patent foramen ovale and thrombophilia, after ischemic stroke, acute coronary syndrome and pulmonary embolism (RCD code: IV-2B.O)
Patent foramen ovale (PFO) is a residue of the foramen ovale, an integral part of the normal fetal circulation. It closes in most of newborns, however 25–30% of adults may have it patent. Conditions such as crytpogenic s...
Facilitating recognition and grouping the expertise in the main fields of rare cardiovascular diseases
Dear Friends and Colleagues, Dear Readers,We are pleased to deliver at your hands the second issue of your quarterly Journal of Rare Cardiovascular Diseases. The feedback we have received, after launching the Journal in...